Inhibition of soluble epoxide hydrolase does not improve the course of congestive heart failure and the development of renal dysfunction in rats with volume overload induced by aorto-caval fistula

Physiol Res. 2015;64(6):857-73. doi: 10.33549/physiolres.932977. Epub 2015 Jun 5.

Abstract

The detailed mechanisms determining the course of congestive heart failure (CHF) and associated renal dysfunction remain unclear. In a volume overload model of CHF induced by creation of aorto-caval fistula (ACF) in Hannover Sprague-Dawley (HanSD) rats we explored the putative pathogenetic contribution of epoxyeicosatrienoic acids (EETs), active products of CYP-450 dependent epoxygenase pathway of arachidonic acid metabolism, and compared it with the role of the renin-angiotensin system (RAS). Chronic treatment with cis-4-[4-(3-adamantan-1-yl-ureido) cyclohexyloxy]benzoic acid (c-AUCB, 3 mg/l in drinking water), an inhibitor of soluble epoxide hydrolase (sEH) which normally degrades EETs, increased intrarenal and myocardial EETs to levels observed in sham-operated HanSD rats, but did not improve the survival or renal function impairment. In contrast, chronic angiotensin-converting enzyme inhibition (ACEi, trandolapril, 6 mg/l in drinking water) increased renal blood flow, fractional sodium excretion and markedly improved survival, without affecting left ventricular structure and performance. Hence, renal dysfunction rather than cardiac remodeling determines long-term mortality in advanced stage of CHF due to volume overload. Strong protective actions of ACEi were associated with suppression of the vasoconstrictor/sodium retaining axis and activation of vasodilatory/natriuretic axis of the renin-angiotensin system in the circulating blood and kidney tissue.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • 8,11,14-Eicosatrienoic Acid / analogs & derivatives
  • 8,11,14-Eicosatrienoic Acid / blood
  • 8,11,14-Eicosatrienoic Acid / metabolism
  • Angiotensin I / blood
  • Angiotensin II / blood
  • Angiotensin-Converting Enzyme Inhibitors
  • Animals
  • Benzoates / pharmacology
  • Benzoates / therapeutic use*
  • Disease Models, Animal
  • Drug Evaluation, Preclinical
  • Epoxide Hydrolases / antagonists & inhibitors*
  • Epoxy Compounds / metabolism
  • Heart Failure / blood
  • Heart Failure / complications
  • Heart Failure / diagnostic imaging
  • Heart Failure / drug therapy*
  • Kidney / metabolism
  • Male
  • Myocardium / metabolism
  • Peptide Fragments / blood
  • Random Allocation
  • Rats
  • Renal Insufficiency / blood
  • Renal Insufficiency / etiology
  • Renal Insufficiency / prevention & control*
  • Renin-Angiotensin System / drug effects
  • Ultrasonography
  • Urea / analogs & derivatives*
  • Urea / pharmacology
  • Urea / therapeutic use

Substances

  • 4-(4-(3-adamantan-1-ylureido)cyclohexyloxy)benzoic acid
  • Angiotensin-Converting Enzyme Inhibitors
  • Benzoates
  • Epoxy Compounds
  • Peptide Fragments
  • Angiotensin II
  • Urea
  • Angiotensin I
  • Epoxide Hydrolases
  • 8,11,14-Eicosatrienoic Acid
  • angiotensin I (1-7)